Founded in 1991 Biem Pharmaceuticals with headquarters in Ankara, is a privately held pharmaceutical company engaged in manufacturing, distribution and marketing of pharmaceutical and healthcare products.
The company’s strength lies in its unique offerings of a high value pharmaceutical products portfolio on the Turkish and global market, pursuing also partnerships with international leading pharmaceutical companies interested to enter on the domestic pharmaceutical market.
Our succes is an outcome of strategic focus on the pharmaceutical industry, constantly investing and promoting growth and innovation. Over the years, Biem Pharmaceuticals has extended its footprint beyond Turkey and other countries across the globe.
Our expertise lies in manufacturing and licensing of pharmaceutical products, Biem being well positioned to efficiently license, register and commercialize pharmaceutical products in Turkey, and abroad through its international partners.
Our Mission is…
to become the FIRST REMEDY for saving and improving lives through the manufacturing of high-tech, pioneering products which will satisfy the need of customers and ONLY REMEDY able to provide innovative pharmaceutical products without pursuing high profit margins, for illnesses that affects only a small percentage of the population.
In order to achieve this mission we undertake to create value for our customers, consumers and the community.
Our Vision is…
to achieve growth in our therapeutic field with an innovative approach and steady growth, to increase the quality of our health services in all its activities, while preserving the ethical values of the health industry,
always focused to produce the best quality products, safe and efficient, by searching innovative solutions for happy and healthy lifes.
Milestones
1991
Establishment
Biem becomes exclusive distributer of Cutter USA and becomes a limited company within the year.
2011
Distributer
Until 2011 Biem was distributer of Export volume increased
Cutter & Miles / Bayer / Talecris
2012-14
CT, MR Contrast and Oncology-Hematology
Launch of CT, MR Contrast and Oncology-Hematology Portfolio
2015
New Launches
Launch of Intensive Care product portfolio
2019
Expanding Product Portfolio
Expanded portfolio to 43 products
2022
Export Milestone
Export volume increased to 32 countries.
2024
Factory
Completed construction of the manufacturing site (30.000 m² closed area)
2024
Initial Public Offering
Biem received the preliminary approval for its initial
public offering (IPO), stepping into a new phase in investment
2025
Globaly Growing Presence
80+ MA approvals have been obtained in more than 30 countries.